The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Also Read: Analyst Initiates Coverage On ‘Undervalued' Summit Therapeutics The trial met its primary endpoint of progression-free survival (PFS). At a prespecified interim analysis conducted by ...

The drug was the centerpiece in BMS’ $14 billion acquisition of Karuna Therapeutics, and it’s one of the most closely watched blockbuster hopefuls in the Big Pharma company’s portfolio.

By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that would help expand its ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a late-stage trial studying it as an add-on treatment for schizophrenia, ...

April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that ...

SEATTLE, April 22, 2025 /PRNewswire-PRWeb/ -- Transneural Therapeutics, Inc. (Transneural), a preclinical-stage biotechnology company aiming to transform the treatment of neuropsychiatric and ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX) just announced today that it had received IND clearance from the FDA for its BTK degrader GS-6791, which is being developed to target inflammatory disorders.

She has a longstanding interest in developing better treatments for schizophrenia having served on the Board of Karuna Therapeutics prior to their successful acquisition by Bristol Myers Squibb ...